Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-52944-6
Abstract: Several ongoing clinical trials are investigating the use of immuno-targeting therapy with programmed cell death protein-1 and programmed death-ligand 1 (PD-L1) inhibitors for triple-negative breast cancer. However, the role of PD-L1 expression in HER2-positive breast… read more here.
Keywords: her2 positive; positive breast; breast cancer; cancer ... See more keywords
RA10.01: TREATMENT STRATEGY OF ESOPHAGEAL CANCER FROM THE EXPRESSION OF HER2 AND EGFR
Sign Up to like & getrecommendations! Published in 2018 at "Diseases of the Esophagus"
DOI: 10.1093/dote/doy089.ra10.01
Abstract: Neo-adjuvant chemotherapy (NAC) became to be a standard therapeutic strategy for advanced esophageal squamous cell carcinoma in Japan. However the multidrug combination chemotherapy with 5-FU, cisplatin (FP) and docetaxel (DFP) has been well known more… read more here.
Keywords: response; expression; her2 egfr; her2 ... See more keywords
Expression of ER, PR, HER2, and Cadherin tumor markers in a series of Saudi patients with BC.
Sign Up to like & getrecommendations! Published in 2022 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_202205_28849
Abstract: OBJECTIVE Breast cancer (BC) tumor markers have an important implication in the subsequent BC management and survival determinants. Thus, the present study aimed to formulate the expression of ER, PR, HER2, and E-cadherin tumor markers… read more here.
Keywords: saudi patients; expression her2; tumor markers; her2 cadherin ... See more keywords